Celgene settles U.S. patent litigation for top seller Revlimid

(Reuters) - Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire.

Source: Reuters: Health - December 22, 2015 Category: Consumer Health News Tags: healthNews Source Type: news